BID

Across TCGA pan-cancer cohorts, BID Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated BID data layer compared with 21 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher BID Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated BID expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

COAD, ESCA, and UCEC are the cancer types where BID Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	All	0.195	0.680	.020	10	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →
UCEC	DFS	Median	All	1.000	0.628	.029	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

BID–COAD (OS)

Open the COAD breakdown →